CAS 170851-70-4 : Ipamorelin 38 H 49 N 9 O 5 Ipamorelin [INN] 2-Methylalanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide Unii-Y9M3S784Z6 2-methylalanyl-L-histidyl-3-naphthalen-2-yl-D-alanyl-D-phenylalanyl-L-lysinamide 8 products
The treatment efficacy was time dependent with a mild protective effect when applied 4.5 hours after stroke and no effect after 8 hours
United States America 97 (17), 94089412
Timothy Piatkowski, a senior research fellow at the University of Queenslands Centre for Health Services Research specialising in performance enhancing drugs (who has himself dabbled with products like BPC-157 in the past) says that such synthetic peptides have been popular in bodybuilding circles for more than a decade
CASTA, the Cerebrolysin Acute Stroke Treatment in Asia trial, randomized 1,070 patients within twelve hours of an ischemic stroke to either 30 mL of cerebrolysin a day for ten days on top of aspirin, or to a saline placebo (Heiss et al., Stroke 2012, phase 3)
